同期推量放射治疗食管癌的疗效分析  

Analysis of the therapeutic effect of simultaneous integrated boost radiotherapyin the treatment of esophageal cancer

作　　者：韩翔[1] 毕晓蕾 窦超超 邢晓波 张真[1] HAN Xiang;BI Xiao-lei;DOU Chao-chao;XING Xiao-bo;ZHANG Zhen(The First Department of Radiotherapy,Qingdao Central Hospital Affiliated to Qingdao University,Qingdao 266042,China;Department of Joint and Sports Medicine,Qingdao Central Hospital Affiliated to Qingdao University,Qingdao 266042,China)

机构地区：[1]青岛大学附属青岛市中心医院放一科,山东青岛266042 [2]青岛大学附属青岛市中心医院关节与运动医学科,山东青岛266042

出　　处：《实用医院临床杂志》2021年第5期153-155,共3页Practical Journal of Clinical Medicine

摘　　要：目的分析采用同期推量调强放疗(SIB-IMRT)治疗食管癌的疗效及不良反应。方法69例食管癌患者分为同期推量组及序贯组,同期推量组PGTVnx、PGTVnd 2.14 Gy/f,PTV 1.8 Gy/f,28 f;序贯组PTV 2 Gy/f,25 f,结束后给予局部肿瘤及转移淋巴结加量,2 Gy/f,5 f。比较两组有效率、不良反应、6个月及1年生存率。结果同期推量组有效率为84.2%,两组间比较差异无统计学意义(P>0.05)。两组6个月及1年生存率比较,差异无统计学意义(P>0.05)。同期推量组放射性肺炎发生率明显降低,差异有统计学意义(P<0.05)。结论同期推量调强放疗治疗食管癌疗效相当,副作用较小,可做为首选方案。Objective To analyze the clinical curative effect and adverse effects of simultaneous integrated boost radiotherapyand intensity-modulated radiation therapy(SIB-IMRT)in the treatment of esophageal cancer.Methods Sixty-ninepatients with esophageal cancer were randomly divided into simultaneous integrated boost or sequential integrated boost group.In the simultaneous integrated boost group,the whole dose of plan gross tumor volume(PGTV)was 2.14 Gy/fraction and the whole dose of plan gross volume(PTV)was 1.8Gy/fraction in 28 fractions.In the sequential integrated boost group,PGTVwas 2 Gy/fraction in 25 fractions,and then added 2 Gy/fraction for another 5 fractions.The effective rate,adverse effects,six-month and one-year survival rate were compared between the two groups.Results The effective rate of the simultaneous integrated boost group was 84.2%but there was no statistical significance between the two groups(P>0.05).There was no significant difference between 6-month and one-year survival rate between the two groups(P>0.05).The incidence of radiation pneumonitis in the simultaneous integrated boost group was lower than that in the sequential integrated boost group.Conclusion SIB-IMRT has a good clinical curative effecandless adverse effectsin the treatment of esophageal cancer.It's feasible to be used.

关 键 词：食管癌 同期推量 放疗 

分 类 号：R735.1[医药卫生—肿瘤]